NuCana (NCNA) Competitors $0.04 0.00 (-8.86%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$0.04 +0.00 (+1.02%) As of 08/1/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock NCNA vs. BPTH, VAXX, ZVSA, ASLN, EVFM, OGEN, NMTR, PTPI, TRVN, and PBLAShould you be buying NuCana stock or one of its competitors? The main competitors of NuCana include Bio-Path (BPTH), Vaxxinity (VAXX), ZyVersa Therapeutics (ZVSA), ASLAN Pharmaceuticals (ASLN), Evofem Biosciences (EVFM), Oragenics (OGEN), 9 Meters Biopharma (NMTR), Petros Pharmaceuticals (PTPI), Trevena (TRVN), and Panbela Therapeutics (PBLA). These companies are all part of the "pharmaceutical products" industry. NuCana vs. Its Competitors Bio-Path Vaxxinity ZyVersa Therapeutics ASLAN Pharmaceuticals Evofem Biosciences Oragenics 9 Meters Biopharma Petros Pharmaceuticals Trevena Panbela Therapeutics Bio-Path (NASDAQ:BPTH) and NuCana (NASDAQ:NCNA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, analyst recommendations, institutional ownership, dividends, valuation and profitability. Is BPTH or NCNA more profitable? NuCana's return on equity of -319.85% beat Bio-Path's return on equity.Company Net Margins Return on Equity Return on Assets Bio-PathN/A -2,842.40% -337.48% NuCana N/A -319.85%-88.55% Which has higher earnings and valuation, BPTH or NCNA? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBio-PathN/AN/A-$16.08MN/AN/ANuCanaN/AN/A-$24.28M-$7.02-0.01 Which has more risk & volatility, BPTH or NCNA? Bio-Path has a beta of -0.03, indicating that its stock price is 103% less volatile than the S&P 500. Comparatively, NuCana has a beta of 1.41, indicating that its stock price is 41% more volatile than the S&P 500. Do insiders & institutionals hold more shares of BPTH or NCNA? 5.7% of Bio-Path shares are held by institutional investors. Comparatively, 44.0% of NuCana shares are held by institutional investors. 0.7% of Bio-Path shares are held by company insiders. Comparatively, 31.2% of NuCana shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Do analysts prefer BPTH or NCNA? NuCana has a consensus price target of $25.00, suggesting a potential upside of 63,838.62%. Given NuCana's stronger consensus rating and higher possible upside, analysts plainly believe NuCana is more favorable than Bio-Path.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bio-Path 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00NuCana 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Does the media refer more to BPTH or NCNA? In the previous week, NuCana had 2 more articles in the media than Bio-Path. MarketBeat recorded 3 mentions for NuCana and 1 mentions for Bio-Path. NuCana's average media sentiment score of -0.33 beat Bio-Path's score of -1.00 indicating that NuCana is being referred to more favorably in the news media. Company Overall Sentiment Bio-Path Negative NuCana Neutral SummaryNuCana beats Bio-Path on 10 of the 11 factors compared between the two stocks. Get NuCana News Delivered to You Automatically Sign up to receive the latest news and ratings for NCNA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NCNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NCNA vs. The Competition Export to ExcelMetricNuCanaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$260K$3.00B$5.49B$9.54BDividend YieldN/A2.43%4.73%4.09%P/E Ratio-0.0117.7428.8323.83Price / SalesN/A179.21372.0766.02Price / CashN/A41.9535.4557.96Price / Book0.038.508.275.54Net Income-$24.28M-$55.06M$3.25B$259.28M7 Day PerformanceN/A-3.99%-3.73%-4.68%1 Month PerformanceN/A9.58%4.29%4.36%1 Year PerformanceN/A6.70%25.87%17.88% NuCana Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NCNANuCana2.6727 of 5 stars$0.04-8.9%$25.00+63,838.6%-98.9%$260KN/A-0.0130News CoverageShort Interest ↑Gap UpBPTHBio-Path0.5791 of 5 stars$0.15+4.5%N/A-90.0%$1.27MN/A0.0010Short Interest ↑VAXXVaxxinityN/A$0.01-77.3%N/A-99.7%$1.27MN/A-0.0290Gap DownZVSAZyVersa Therapeutics0.3983 of 5 stars$0.26-5.6%N/A-94.6%$1.24MN/A0.002Upcoming EarningsGap DownASLNASLAN PharmaceuticalsN/A$0.60flatN/AN/A$1.23M$12M-0.0330EVFMEvofem Biosciences0.756 of 5 stars$0.01+3.1%N/A-9.0%$1.19M$11.39M-0.02120Short Interest ↑OGENOragenics0.2213 of 5 stars$1.38-0.7%N/A-95.9%$1.14MN/A-0.205News CoverageNMTR9 Meters BiopharmaN/AN/AN/AN/A$1.04MN/A-0.0220PTPIPetros PharmaceuticalsN/A$0.03-2.9%N/A-99.7%$938K$5.11M-0.0120Gap DownTRVNTrevena1.5454 of 5 stars$0.91flat$5.00+449.5%-82.5%$873K$443K-0.0240Upcoming EarningsPBLAPanbela Therapeutics0.1643 of 5 stars$0.16flatN/A-55.3%$767KN/A0.006Short Interest ↑ Related Companies and Tools Related Companies Bio-Path Competitors Vaxxinity Competitors ZyVersa Therapeutics Competitors ASLAN Pharmaceuticals Competitors Evofem Biosciences Competitors Oragenics Competitors 9 Meters Biopharma Competitors Petros Pharmaceuticals Competitors Trevena Competitors Panbela Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NCNA) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NuCana PLC Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share NuCana With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
